Roche’s megablock­buster MS can­di­date ocre­lizum­ab posts promis­ing head-to-head da­ta

By most ac­counts, Roche’s ocre­lizum­ab is like­ly the biggest drug in the in­dus­try’s late-stage pipeline, with peak rev­enue po­ten­tial rang­ing up to a megablock­buster $7 bil­lion or so. And to­day the com­pa­ny whet the ap­petite of an­a­lysts with a head-to-head com­par­i­son with Mer­ck KGaA’s Rebif – al­ready un­der as­sault from Tec­fidera (Bio­gen), Gilenya (No­var­tis) and Auba­gio (Sanofi) – that makes the new drug look even bet­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER